Immune Checkpoint Inhibitors for the Treatment of Bladder Cancer

Immune Checkpoint Inhibitors for the Treatment of Bladder Cancer

A number of immune checkpoint inhibitors (ICIs) have been approved as first-line therapy in case of cisplatin-ineligible patients or as second-line therapy for patients with metastatic urothelial carcinoma (mUC) of the bladder. About 30% of patients with mUC will respond to ICIs immunotherapy. Progr...

Full description

Bibliographic Details
Main Authors: Antonio Lopez-Beltran, Alessia Cimadamore, Ana Blanca, Francesco Massari, Nuno Vau, Marina Scarpelli, Liang Cheng, Rodolfo Montironi
Format: Article
Language:English
Published: MDPI AG 2021-01-01
Series:Cancers
Subjects:
bladder cancer
variant histology
urothelium
PD-1
PD-L1
immunotherapy
Online Access:https://www.mdpi.com/2072-6694/13/1/131

Internet

https://www.mdpi.com/2072-6694/13/1/131

Similar Items